Recent Updates
Recently added Catalysts

ANEB-001

Phase 2

Acute Cannabinoid Intoxication | Small molecule | Other |Anebulo Pharmaceuticals, Inc.|Last Updated: Aug 29, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment154
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05282797Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge TestPHASE2 COMPLETED 154Dec 15, 2021Aug 26, 2023Aug 29, 20231 Netherlands
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Subjective Feeling High
Day 1

Feeling High on a visual analog scale (mm)

Postural stability
Day 1

Body sway (mm);

Subjective Alertness
Day 1

Alertness on a visual analog scale (mm)

Heart Rate
Day 1

Heart Rate in beats/min

Secondary Endpoints
Subjective Mood
Day 1
Subjective Calmness
Day 1
Feeling of Drug Effect
Day 1
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part A - ANEB-001EXPERIMENTALSubjects receive THC and varying amounts of ANEB-001
Part A - PlaceboPLACEBO_COMPARATORSubjects receive THC and placebo
Part B - Cohort 1 - ANEB-001EXPERIMENTALSubjects receive 21 mg of THC and 30 mg of ANEB-001
Part B - Cohort 1 - PlaceboPLACEBO_COMPARATORSubjects receive 21 mg of THC and placebo
Part B - Cohort 2 - ANEB-001EXPERIMENTALSubjects receive 21 mg of THC and 10 mg of ANEB-001
Part B - Cohort 2 - PlaceboPLACEBO_COMPARATORSubjects receive 21 mg of THC and placebo
Part B - Cohort 3 - ANEB-001EXPERIMENTALSubjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001
Part B - Cohort 3 - PlaceboPLACEBO_COMPARATORSubjects receive 21 mg THC and 1 hour later, placebo
Part B - Cohort 4 - ANEB-001EXPERIMENTALSubjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001
Part B - Cohort 4 - PlaceboPLACEBO_COMPARATORSubjects receive 40 mg of THC and 1 hour later, placebo
Part B - Cohort 5 - ANEB-001EXPERIMENTALSubjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
Part B - Cohort 5 - PlaceboPLACEBO_COMPARATORSubjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001
Part B - Cohort 6 - ANEB-001EXPERIMENTALSubjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001
Part B - Cohort 6 - PlaceboPLACEBO_COMPARATORSubjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo
Part C - Cohort 7 - ANEB-001EXPERIMENTALSubjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001
Part C - Cohort 8 - ANEB-001EXPERIMENTALSubjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001
Interventions
NameTypeDescription
ANEB-001DRUGExperimental Treatment
PlaceboDRUGPlacebo comparator
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Signed informed consent prior to any study-mandated procedure * BMI between 18 and 30 kg/m2 * Minimum weight 50 kg * Occasional cannabis user Exclusion Criteria: * Evidence of active or chronic condition that could interfere with, or which the treatment of might interfere wi...

Countries:Netherlands
Unlock Eligibility Criteria